Asparaginase Erwinia chrysanthemi
- Generic Name
- Asparaginase Erwinia chrysanthemi
- Brand Names
- Erwinaze, Rylaze, Enrylaze
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1349719-22-7
- Unique Ingredient Identifier
- D733ET3F9O
- Background
Asparaginase Erwinia chrysanthemi is an asparaginase-specific enzyme derived from Erwinia chrysanthemi used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and ther...
- Indication
Asparaginase Erwinia chrysanthemi is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in adults and children who have developed hypersensitivity to E. coli-derived asparaginase.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Lymphoblastic Lymphoma
- Associated Therapies
- -
A Study of Erwinaze Administered Intravenously in Patients Who Had an Allergy to Frontline Asparaginase Therapy
- Conditions
- Interventions
- First Posted Date
- 2012-07-18
- Last Posted Date
- 2021-06-23
- Lead Sponsor
- Jazz Pharmaceuticals
- Target Recruit Count
- 30
- Registration Number
- NCT01643408
- Locations
- 🇺🇸
John Hopkins, Baltimore, Maryland, United States
🇺🇸Children's Hospital of Los Angeles, Los Angeles, California, United States
🇨🇦Hospital St. Justine, Saint Catherine, Quebec, Canada
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2011-10-13
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 23
- Registration Number
- NCT01451515
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224)
- First Posted Date
- 2009-06-25
- Last Posted Date
- 2019-02-19
- Target Recruit Count
- 1
- Registration Number
- NCT00928200
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2008-06-09
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 87
- Registration Number
- NCT00693602
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Erwinase Master Treatment Protocol
- First Posted Date
- 2008-01-11
- Last Posted Date
- 2012-04-12
- Lead Sponsor
- Phoenix Children's Hospital
- Registration Number
- NCT00590915
Erwinase Study in Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2007-07-25
- Last Posted Date
- 2014-09-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 33
- Registration Number
- NCT00506597
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Association of L-asparaginase-Methotrexate-Dexamethasone for Nasal and Nasal-type Natural Killer (NK)-T-cell Lymphoma
- Conditions
- First Posted Date
- 2006-01-31
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- University Hospital, Limoges
- Target Recruit Count
- 40
- Registration Number
- NCT00283985
- Locations
- 🇫🇷
Service d'Hématologie, Evry, France
🇫🇷Département Maladies du Sang, Angers, France
🇫🇷CH Annecy, Annecy, France
A Study of Children With Refractory or Relapsed ALL
- Conditions
- Interventions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT00187083
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.